Recurrent renal cancer presents unique challenges for patients who have already undergone treatment for kidney cancer. Understanding the options available, from established therapies to innovative approaches being tested in clinical trials, can help patients and their families navigate this difficult phase with greater confidence and clarity.

Managing Cancer That Returns After Treatment

When kidney cancer comes back after initial treatment, it is called recurrent renal cancer. This situation can be emotionally difficult and medically complex. The cancer may reappear in the same location where the original tumor was, in the remaining kidney tissue, or in other parts of the body such as the lungs, bones, brain, or lymph nodes. Studies show that approximately one in five people who have surgery to remove kidney cancer confined to the kidney will experience a recurrence at some point in their lives^[1][5].

The timing of recurrence varies significantly. About half of all recurrences happen within the first two years after surgery, but cancer can return much later—even ten years or more after the initial treatment^[1][2][6]. This unpredictable timeline highlights the importance of long-term follow-up care. Some patients have experienced recurrences decades after their first surgery, emphasizing that kidney cancer survivors need ongoing monitoring rather than assuming they are completely free of risk after a few years^[2].

The approach to treating recurrent kidney cancer depends on several factors. These include where the cancer has returned, which treatments were used previously, the patient’s overall health, and how well the remaining kidney is functioning. The goal of treatment may be to eliminate the cancer entirely if it is localized, to slow its growth and spread if it has metastasized, or to manage symptoms and maintain quality of life.

Factors That Influence the Risk of Recurrence

Not everyone who has kidney cancer surgery faces the same risk of recurrence. Healthcare providers use various factors to estimate an individual patient’s risk. Understanding these factors can help patients and doctors develop appropriate monitoring and treatment plans.

One of the strongest predictors of recurrence is the stage of the cancer at the time of initial diagnosis and treatment. Stage refers to how large the tumor was and whether it had spread beyond the kidney. Patients with stage I cancer, where the tumor was small and confined to the kidney, have a much lower risk of recurrence than those with stage II or stage III disease, where the tumor was larger or had begun to spread to nearby tissues^[6]. The ten-year survival rates without recurrence are approximately 94.5% for stage T1a disease, 75% for T1b, and 57.9% for T2 disease^[6].

The grade of the cancer also matters significantly. Grade describes how abnormal the cancer cells look under a microscope. Higher-grade cancers, where cells look very different from normal kidney cells, are more aggressive and more likely to return^[1][6].

The type of kidney cancer influences recurrence risk as well. Clear cell renal cell carcinoma, the most common type, behaves differently than other subtypes. Certain types have higher chances of recurring after treatment^[1][6].

The type of surgery performed may play a role. Patients who had a partial nephrectomy—where only the tumor and a small amount of surrounding kidney tissue were removed—have a slightly higher chance of local recurrence compared to those who had a radical nephrectomy, where the entire kidney was removed. This happens because if any cancer cells remain in the kidney tissue after partial surgery, they could potentially grow again^[1]. However, the overall difference in recurrence rates between the two types of surgery is relatively small^[5].

Other factors include the patient’s age at diagnosis, with younger patients generally having more time for cancer to recur, and whether the patient has a genetic condition that increases kidney cancer risk, such as von Hippel-Lindau syndrome^[1]. A family history of kidney cancer also raises the possibility of genetic factors that could increase recurrence risk.

Standard Treatment Approaches for Recurrent Kidney Cancer

When kidney cancer returns, several established treatment methods are available. The choice of treatment depends on where the cancer has reappeared and the patient’s individual circumstances.

Targeted Therapy

Targeted therapy is considered the main treatment for recurrent kidney cancer^[4][9]. Unlike traditional chemotherapy, which attacks all rapidly dividing cells in the body, targeted therapy drugs are designed to attack specific molecules involved in cancer cell growth and survival. This approach often causes fewer side effects than chemotherapy.

One important group of targeted therapy drugs works by blocking vascular endothelial growth factor (VEGF). VEGF is a protein that helps tumors grow new blood vessels to supply themselves with nutrients and oxygen. By blocking VEGF, these drugs essentially starve the tumor. Commonly used VEGF inhibitors include sorafenib (Nexavar), pazopanib (Votrient), axitinib (Inlyta), sunitinib (Sutent), and cabozantinib (Cabometyx)^[4][9].

Another target is mammalian target of rapamycin (mTOR), a protein that helps cells grow and divide. Drugs that inhibit mTOR include temsirolimus (Torisel) and everolimus (Afinitor)^[4][9].

A third category targets tyrosine kinase, a protein on the surface of cells that sends growth signals. Lenvatinib (Lenvima) is a tyrosine kinase inhibitor that may be used in combination with everolimus for patients who have previously received VEGF-targeted therapy^[4][9].

These medications are typically taken by mouth daily. The duration of treatment varies depending on how well the cancer responds and what side effects the patient experiences. Common side effects can include fatigue, diarrhea, high blood pressure, hand-foot syndrome (redness, pain, and swelling on the palms and soles), loss of appetite, and changes in liver function. Most side effects can be managed with dose adjustments, additional medications, or supportive care.

Immunotherapy

Immunotherapy represents an important treatment option for recurrent kidney cancer, particularly when the cancer no longer responds to targeted therapy. Immunotherapy works differently from other cancer treatments—it helps the patient’s own immune system recognize and destroy cancer cells.

Kidney cancer cells can sometimes hide from the immune system by activating certain “checkpoint” proteins that turn off immune responses. Immune checkpoint inhibitors are drugs that block these proteins, essentially removing the brakes from the immune system and allowing it to attack cancer cells. Nivolumab (Opdivo) is one such drug that may be offered when kidney cancer stops responding to VEGF-targeted drugs^[4][9]. Sometimes nivolumab is combined with another immune checkpoint inhibitor called ipilimumab (Yervoy) for enhanced effect.

Immunotherapy is given through intravenous infusion, typically every few weeks. Because it works by stimulating the immune system, the side effects are different from those of chemotherapy or targeted therapy. The immune system may become overactive and attack healthy tissues, causing inflammation in various organs. Common side effects include fatigue, rash, diarrhea, and changes in hormone levels, particularly affecting the thyroid gland. More serious but rare side effects can involve inflammation of the lungs, liver, intestines, or other organs. These autoimmune reactions require prompt medical attention and are usually treated with steroids to calm the immune response.

Surgery for Recurrent Disease

In carefully selected cases, surgery can be an option for recurrent kidney cancer. If the cancer has returned in a localized area and can be completely removed, surgery may improve outcomes^[4][9][11].

For patients who had a partial nephrectomy initially, repeat surgery might involve removing more kidney tissue or even the entire remaining kidney, a procedure called completion nephrectomy. For those with recurrence in the kidney bed (the area where the kidney was removed), surgery to excise the recurrent tumor may be possible^[11].

A specialized type of surgery called cytoreductive nephrectomy may be performed before starting targeted therapy. This involves removing the kidney containing the tumor along with as much cancer as possible. Even if all cancer cannot be removed, reducing the tumor burden may help targeted therapy work better^[4][9].

When kidney cancer spreads to other organs, surgery to remove those metastases (metastasectomy) is sometimes performed. The lungs and brain are common sites where surgical removal of isolated metastases can be beneficial^[4].

Repeat kidney surgery is generally more complicated than the initial operation due to scar tissue and changes in anatomy from the previous procedure. The risk of complications, including bleeding, infection, and injury to nearby structures, is higher. Recovery time varies but can take several weeks to months. However, in experienced hands and for appropriately selected patients, repeat surgery can provide good cancer control and may extend survival^[11].

Radiation Therapy

While kidney cancer is generally considered resistant to traditional radiation therapy, external beam radiation can be useful for managing symptoms and treating specific sites of recurrence^[4][9].

Radiation therapy is particularly valuable when kidney cancer spreads to the bones, where it can cause significant pain and risk of fracture. Radiation to bone metastases can relieve pain and strengthen the bone. Similarly, if cancer spreads to the brain, radiation can help control symptoms and prevent further neurological problems.

For patients who are not well enough to receive targeted therapy or undergo surgery, radiation therapy can help control bleeding, reduce pain, and manage other symptoms to maintain quality of life.

Stereotactic body radiation therapy (SBRT) is a more precise form of radiation that delivers high doses to small, well-defined areas. This technique may be considered for patients with limited sites of recurrence who are not surgical candidates.

Ablation Therapy

Ablation therapy uses extreme temperatures to destroy cancer tissue. This approach may be offered to patients who cannot undergo surgery or targeted therapy due to other health conditions^[4][9].

The two main types of ablation are radiofrequency ablation, which uses heat, and cryoablation, which uses extreme cold to freeze and destroy tumor cells. These procedures are typically performed by interventional radiologists using imaging guidance to precisely target the tumor.

Ablation is generally less invasive than surgery, often performed through small incisions or needles inserted through the skin. Recovery is usually quicker than from surgery. However, ablation is typically only suitable for smaller tumors in accessible locations.

Innovative Treatments in Clinical Trials

Research into new treatments for recurrent kidney cancer is ongoing, with numerous clinical trials investigating promising approaches. These trials test new drugs, new combinations of existing drugs, and entirely novel treatment strategies.

Combination Immunotherapy and Targeted Therapy

One of the most significant advances in kidney cancer treatment has been the combination of immune checkpoint inhibitors with targeted therapy drugs. Clinical trials have demonstrated that combining these two approaches can be more effective than using either alone.

Several combination regimens have been studied extensively. Pembrolizumab (an immune checkpoint inhibitor) combined with axitinib (a VEGF inhibitor) has shown promising results in clinical trials for advanced kidney cancer^[15]. Another combination, avelumab (another checkpoint inhibitor) with axitinib, has also demonstrated benefit.

The rationale behind these combinations is that they attack cancer through two different mechanisms simultaneously. The VEGF inhibitor disrupts the tumor’s blood supply while the immune checkpoint inhibitor helps the immune system attack cancer cells. This dual approach may overcome resistance that develops to single-agent therapy.

These combination treatments are being tested in various settings, including for patients with newly diagnosed metastatic disease and those with recurrent cancer. The trials are conducted in multiple phases. Phase I trials test safety and determine appropriate doses. Phase II trials evaluate whether the treatment shows evidence of working against cancer. Phase III trials compare the new treatment to standard treatment to determine if it offers superior outcomes.

Side effects from combination therapy can be more significant than from single-agent treatment, as patients may experience side effects from both drugs. Careful monitoring and management of side effects is essential.

Adjuvant Immunotherapy to Prevent Recurrence

A major development in kidney cancer treatment has been the study of therapies given after surgery to reduce the risk of cancer returning. This approach is called adjuvant therapy.

In 2021, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda) as adjuvant therapy for patients who have had surgery to remove kidney cancer and are at high risk of recurrence^[14]. This was the first immunotherapy approved for this purpose.

The approval was based on results from the KEYNOTE-564 clinical trial, which showed that pembrolizumab reduced the risk of cancer recurrence or death by 32% compared to placebo. At the two-year mark, 78.3% of patients receiving pembrolizumab were disease-free compared to 67.3% of those receiving placebo^[14].

Pembrolizumab is given intravenously every three weeks for up to one year. The most common side effects include fatigue, musculoskeletal pain, rash, diarrhea, and itching. About 8% of patients in the trial required steroid treatment to manage side effects, and approximately 20% had to stop treatment early due to side effects^[14].

This treatment represents what researchers call “curative potential”—the possibility of preventing cancer from returning altogether rather than just treating it after recurrence. However, adjuvant immunotherapy is not suitable for everyone. It is typically recommended for patients with intermediate-high to high risk of recurrence, such as those with stage III clear cell kidney cancer or tumors with high-grade or sarcomatoid features^[14][15].

Deciding whether to undergo adjuvant immunotherapy involves careful discussion with the healthcare team about the potential benefits versus the risks and commitment involved. Patients must weigh the possibility of preventing recurrence against the side effects and the time commitment of regular infusions for a full year.

Novel Targeted Therapy Drugs

Researchers continue to identify new molecular targets involved in kidney cancer growth and are developing drugs to attack these targets. Clinical trials are testing various experimental compounds at different stages of development.

Some trials focus on drugs that target newly discovered proteins or pathways that cancer cells use to survive and grow. Others investigate whether existing targeted therapy drugs might work better in different combinations or sequences.

One area of investigation involves drugs that target the HIF pathway (hypoxia-inducible factor pathway), which is often abnormal in clear cell kidney cancer. Another involves drugs targeting MET, a protein that promotes cancer cell growth and spread.

These newer agents are typically tested first in Phase I trials to establish safe dosing and identify side effects. If they show promise, they move to Phase II trials to see if they actually shrink tumors or slow disease progression. Drugs that prove effective in Phase II move to Phase III trials, where they are compared directly to standard treatments.

Advanced Imaging and Precision Medicine

Clinical trials are also investigating how better diagnostic tools can help personalize treatment for recurrent kidney cancer. This includes using advanced imaging techniques to detect recurrence earlier and molecular testing to understand the specific genetic changes in a patient’s tumor.

Biomarker studies aim to identify which patients are most likely to benefit from specific treatments based on the molecular characteristics of their cancer. For example, researchers are investigating blood tests that can predict response to immunotherapy or identify patients whose cancer is likely to be resistant to certain targeted therapies.

Accessing Clinical Trials

Clinical trials are conducted at cancer centers and research hospitals around the world, including in the United States, Europe, and many other regions. Patients interested in participating in a clinical trial should discuss this option with their oncologist.

Eligibility for clinical trials depends on many factors, including the type and stage of cancer, previous treatments received, overall health status, and specific trial requirements. Not every trial is appropriate for every patient, but exploring trial options can provide access to cutting-edge treatments that are not yet widely available.

Monitoring and Follow-Up After Treatment

Regular monitoring is essential for detecting recurrence early and managing long-term health after kidney cancer treatment. The frequency and type of follow-up tests depend on the initial cancer stage, treatment received, and individual risk factors.

Follow-up typically includes physical examinations, blood tests to check kidney function, and imaging studies such as CT scans, MRI, or ultrasound to check for signs of recurrence^[1][2]. Blood pressure monitoring is also important, as patients with one kidney or reduced kidney function may be more prone to hypertension.

During the first few years after treatment, when recurrence risk is highest, follow-up appointments are typically scheduled more frequently—often every three to six months. As time passes without recurrence, the intervals between appointments may gradually lengthen to annual visits. However, because late recurrence is possible even after ten years, some degree of ongoing monitoring should continue indefinitely^[2][6].

Patients should report any new symptoms to their healthcare team promptly, including blood in the urine, persistent back or side pain, unexplained weight loss, persistent fatigue, bone pain, or neurological symptoms. While these symptoms don’t necessarily indicate recurrence, they warrant evaluation.

The ASSURE Nomogram is a mathematical tool that healthcare providers may use to estimate an individual patient’s risk of recurrence based on factors such as age, tumor characteristics, and surgical findings^[1]. This risk assessment can help guide decisions about how intensive follow-up monitoring should be.

Most common treatment methods

• Targeted Therapy
  • VEGF inhibitors such as sorafenib, pazopanib, axitinib, sunitinib, and cabozantinib that block blood vessel formation in tumors
  • mTOR inhibitors including temsirolimus and everolimus that interfere with cancer cell growth and division
  • Tyrosine kinase inhibitors like lenvatinib that block growth signals in cancer cells
  • Generally taken orally on a daily basis
  • Side effects may include fatigue, diarrhea, high blood pressure, hand-foot syndrome, and liver function changes
• Immunotherapy
  • Checkpoint inhibitors such as nivolumab and ipilimumab that help the immune system attack cancer cells
  • Given through intravenous infusion every few weeks
  • Used when cancer no longer responds to targeted therapy or as adjuvant treatment after surgery
  • May cause immune-related side effects including fatigue, rash, diarrhea, and thyroid problems
  • Pembrolizumab approved as adjuvant therapy to reduce recurrence risk in high-risk patients after surgery
• Surgery
  • Cytoreductive nephrectomy to remove the kidney and as much cancer as possible before systemic therapy
  • Repeat partial nephrectomy or completion nephrectomy for local recurrence
  • Metastasectomy to remove isolated metastases in lungs, brain, or other organs
  • Generally more complex than initial surgery due to scar tissue
  • Recovery can take several weeks to months
• Radiation Therapy
  • External beam radiation to control symptoms, particularly for bone and brain metastases
  • Stereotactic body radiation therapy (SBRT) for precise targeting of limited recurrence sites
  • Helpful for pain relief, bleeding control, and managing other symptoms
  • May be offered when surgery or systemic therapy are not appropriate
• Ablation Therapy
  • Radiofrequency ablation using heat to destroy tumor tissue
  • Cryoablation using extreme cold to freeze and kill cancer cells
  • Less invasive than surgery with faster recovery
  • Suitable for smaller tumors in accessible locations
  • Option for patients who cannot have surgery or systemic therapy
• Combination Therapy
  • Combinations of immune checkpoint inhibitors with VEGF inhibitors
  • Pembrolizumab plus axitinib or avelumab plus axitinib
  • Attacks cancer through multiple mechanisms simultaneously
  • Being tested in clinical trials for various settings
  • May cause more side effects than single-agent therapy

Living Well With One Kidney After Cancer

Many people who have had kidney cancer treatment live with one kidney or reduced kidney function. With appropriate care, one healthy kidney is sufficient to filter blood and maintain normal body functions.

Protecting the remaining kidney is crucial. This includes staying well hydrated by drinking adequate water daily—typically two liters or more unless otherwise advised by a doctor. A kidney-friendly diet emphasizing fruits, vegetables, and limited sodium helps reduce strain on the kidney^[19][23].

Controlling blood pressure is vital, as high blood pressure can damage kidney function over time. Patients should monitor their blood pressure regularly and work with their healthcare team to keep it in a healthy range through lifestyle measures and medication if needed^[19][23].

Maintaining a healthy weight through balanced eating and regular physical activity benefits overall health and reduces the burden on the remaining kidney. Smoking cessation is extremely important, as smoking damages blood vessels, including those in the kidney, and increases the risk of cancer recurrence^[19].

Regular kidney function testing through blood and urine tests helps detect any problems early. Patients should be cautious with medications that can affect kidney function, including certain pain relievers, and should always inform healthcare providers that they have reduced kidney function before receiving any new medications or contrast dye for imaging tests.

Despite living with one kidney, most people can lead active, normal lives. However, it’s wise to avoid activities that could cause kidney injury, such as contact sports, or to take appropriate precautions if participating in such activities. Heavy lifting and strenuous activities should be approached gradually and discussed with the healthcare team^[19].